Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.

BACKGROUND Botulinum neurotoxin (BoNT) complexes consist of neurotoxin and neurotoxin-associated proteins. Hemagglutinin-33 (HA-33) is a member of BoNT type A (BoNT/A) complex. Considering the protective role of HA-33 in preservation of BoNT/A in gastrointestinal harsh conditions and also its adjuvant role, recombinant production of this protein is favorable. Thus in this study, HA-33 was expressed and purified, and subsequently its antigenicity in mice was studied. METHODS Initially, ha-33 gene sequence of Clostridium botulinum serotype A was adopted from GenBank. The gene sequence was optimized and synthesized in pET28a (+) vector. E. coli BL21 (DE3) strain was transformed by the recombinant vector and the expression of HA-33 was optimized at 37°C and 5 h induction time. RESULTS The recombinant protein was purified by nickel nitrilotriacetic acid agarose affinity chromatography and confirmed by immunoblotting. Enzyme Linked Immunoassay showed a high titer antibody production in mice. CONCLUSION The results indicated a highly expressed and purified recombinant protein, which is able to evoke high antibody titers in mice.

[1]  K. Niwa,et al.  HA-33 facilitates transport of the serotype D botulinum toxin across a rat intestinal epithelial cell monolayer. , 2011, FEMS immunology and medical microbiology.

[2]  Y. Fujinaga.  Interaction of Botulinum Toxin with the Epithelial Barrier , 2010, Journal of biomedicine & biotechnology.

[3]  B. Singh,et al.  Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. , 2009, Toxicon : official journal of the International Society on Toxinology.

[4]  Edwin R Chapman,et al.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. , 2008, Molecular biology of the cell.

[5]  Leonard A. Smith,et al.  Botulism: Cause, Effects, Diagnosis, Clinical and Laboratory Identification, and Treatment Modalities , 2007, Disaster Medicine and Public Health Preparedness.

[6]  K. Niwa,et al.  Role of nontoxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium. , 2007, FEMS immunology and medical microbiology.

[7]  K. Niwa,et al.  Four molecules of the 33 kDa haemagglutinin component of the Clostridium botulinum serotype C and D toxin complexes are required to aggregate erythrocytes. , 2005, Microbiology.

[8]  K. Takeshi,et al.  Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. , 2005, Microbiology.

[9]  S. Sharma,et al.  Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. , 2004, Biochemistry.

[10]  Eric A. Johnson,et al.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells , 2003, The Journal of cell biology.

[11]  Eric A. Johnson,et al.  Neurotoxin Gene Clusters in Clostridium botulinum Type A Strains: Sequence Comparison and Evolutionary Implications , 2003, Current Microbiology.

[12]  T. Watanabe,et al.  Characterization and reconstitution of functional hemagglutinin of the Clostridium botulinum type C progenitor toxin. , 2001, European journal of biochemistry.

[13]  M. Collins,et al.  Characterization of the Genes Encoding the Botulinum Neurotoxin Complex in a Strain of Clostridium botulinum Producing Type B and F Neurotoxins , 1998, Current Microbiology.

[14]  R. Stevens,et al.  Biophysical Characterization of the Stability of the 150-Kilodalton Botulinum Toxin, the Nontoxic Component, and the 900-Kilodalton Botulinum Toxin Complex Species , 1998, Infection and Immunity.

[15]  G. Schiavo,et al.  [39] Tetanus and botulism neurotoxins: Isolation and assay , 1995 .

[16]  G. Schiavo,et al.  Tetanus and botulism neurotoxins: isolation and assay. , 1995, Methods in enzymology.

[17]  F. Benfenati,et al.  Botulinum neurotoxins serotypes A and E cleave SNAP‐25 at distinct COOH‐terminal peptide bonds , 1993, FEBS letters.

[18]  L. Tauc,et al.  Botulinum and Tetanus Neurotoxins , 1993, Springer US.

[19]  B. Dasgupta,et al.  Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: Do they share common amino acid sequences and genes? , 1991, Journal of protein chemistry.

[20]  N. Fujii,et al.  Cloning and complete nucleotide sequence of the gene for the main component of hemagglutinin produced by Clostridium botulinum type C , 1990, Infection and immunity.

[21]  C. Hatheway,et al.  Toxigenic clostridia , 1990, Clinical Microbiology Reviews.

[22]  S. Bernstein,et al.  Recombinant DNA Laboratory Manual , 1989 .

[23]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[24]  L. Simpson.  The origin, structure, and pharmacological activity of botulinum toxin. , 1981, Pharmacological reviews.

[25]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[26]  G Morin,et al.  Medical Microbiology , 1940, Nature.